SecBot SecBot
8-K ·Filed Nov 6, 2026

JAGX

Jaguar Health, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed15d 14h ago SEC0001193125-26-451933
8-K context-dependent: Items 7.01
Actionable Insight ▼ Bearish

The broad approval of dilutive proposals (warrant repricing, ELOC floor reduction, increased share plan) signals the company is likely to raise capital at current low prices. Monitor for actual warrant exercises, ELOC draws, and the board's decision on the reverse split ratio, which could trigger a delisting risk if not executed within one year.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$0.4361
T+0 close · Nov 6, 2026 · via day close
Latest settled
−11.40%
T+5 · $0.3864 · next T+20 in 16d
Vs SPY
−9.70%
α at T+5
Latest observation
−7.51%
T+9 · FF3 residual α
  1. T+0 · Nov 9 $0.4361entry
  2. T+1 · 12d ago +0.14%α +0.51% · $0.4367
  3. T+5 · 6d ago −11.40%α −9.70% · $0.3864
  4. T+9 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Jaguar Health stockholders approved all six proposals at a special meeting, including issuance of shares upon exchange of Series Q Preferred Stock and CVP Debt, repricing of warrants to $1.00, increasing the 2014 Stock Incentive Plan by 378,859 shares, a reverse stock split (ratio 1:2 to 1:150), reducing the ELOC floor price from $16.50 to $1.10, and adjournment authority. The reverse stock split was approved under the votes cast standard but not under the majority of outstanding standard. The approvals enable potential dilution and capital structure changes for a micro-cap biotech with a $7M market cap.

Key Facts

  • All six proposals approved by stockholders at November 6, 2026 special meeting.
  • Proposal 1: Issuance of common shares upon exchange of Series Q Preferred Stock and CVP Debt approved (1,770,099 for, 133,740 against).
  • Proposal 2: Repricing of warrants with exercise prices $525-$3,996.60 to $1.00 per share approved (2,424,969 for, 136,390 against).
  • Proposal 3: 2014 Stock Incentive Plan increased by 378,859 shares (14% of fully diluted shares) approved (2,217,959 for, 339,417 against).
  • Proposal 4: Reverse stock split (1:2 to 1:150) approved under votes cast standard but not under majority of outstanding standard (3,551,428 for, 222,394 against).
  • Proposal 5: ELOC floor price reduced from $16.50 to $1.10 per share approved (2,400,107 for, 158,386 against).
  • Proposal 6: Adjournment authority approved (3,386,070 for, 389,712 against).
  • Company market cap is $7M with a normal daily move of 9.3%.
  • Outstanding common shares as of record date: 7,802,102.

Financial Impact

Potential dilution from warrant repricing (up to 4,052 shares at $1.00 vs prior $525-$3,996.60), plus up to 45,511 shares from Series O and 20,260 from Series R preferred dividends; 378,859 new shares authorized under incentive plan (14% of fully diluted shares); ELOC floor price cut to $1.10 enables further equity issuance at low prices; reverse split ratio up to 1:150 authorized.

dilutionshare countequity

Risk Factors

  • Massive potential dilution from multiple equity-linked instruments at a $7M market cap.
  • Reverse stock split not approved under majority of outstanding standard, indicating significant shareholder opposition.
  • ELOC floor price reduction to $1.10 enables further equity sales at very low prices, pressuring the stock.
  • Company has no revenue or earnings data in filing; financial viability uncertain.
  • Document contains text addressed to automated readers.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-451933
Document: d191844dex991.htm0001193125-26-451933
Document: 0001193125-26-451933-index-headers.html0001193125-26-451933
Document: 0001193125-26-451933-index.html0001193125-26-451933
Document: 0001193125-26-451933.txt0001193125-26-451933

Track record

33 reports on JAGX

Performance horizon

7 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +97.54% at T+1 after the Apr 27, 2026 report. 20 of 22 went positive at some point.

Filters
  1. Nov 20, 20261d ago 8-K Bearish 5/10 Entry $0.2877 Now $0.2270 +21.10% settles Feb 19
  2. Nov 16, 20265d ago 8-K Bearish 6/10 Entry $0.3864 Now $0.2270 +41.25% settles Feb 12
  3. Nov 9, 202612d ago 424B5 Bearish 6/10 Entry $0.4361 Now $0.2270 +47.95% settles Feb 5
  4. Nov 6, 202615d ago 8-K Bearish 6/10 Viewing Entry $0.4361 Now $0.2270 +47.95% settles Feb 5
  5. Nov 6, 202616d ago EFFECT Bearish 5/10 Entry $0.4043 Now $0.2270 +43.85% settles Feb 4
  6. Nov 3, 202618d ago S-3/A Bearish 5/10 Entry $0.5575 Now $0.2270 +59.28% settles Feb 1
  7. Nov 3, 202618d ago 8-K Neutral 2/10 Entry $0.5575 Now $0.2270 −59.28% settles Feb 1
  8. Oct 29, 202623d ago DEFA14A Bearish 6/10 Entry $2.04 Now $0.2270 +88.87% settles Jan 27
  9. Oct 28, 202624d ago 8-K Neutral 2/10 Entry $2.04 Now $0.2270 −88.87% settles Jan 27
  10. Oct 22, 20264w ago S-3 Bearish 5/10 Entry $2.04 Now $0.2270 +88.87% settles Jan 21
Showing 10 of 33

US Market Status

Market Closed · Opens Mon (26h 36m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026